NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Balk E, Chung M, Lichtenstein A, et al. Effects of Omega-3 Fatty Acids on Cardiovascular Risk Factors and Intermediate Markers of Cardiovascular Disease. Rockville (MD): Agency for Healthcare Research and Quality (US); 2004 Mar. (Evidence Reports/Technology Assessments, No. 93.)
This publication is provided for historical reference only and the information may be out of date.
Effects of Omega-3 Fatty Acids on Cardiovascular Risk Factors and Intermediate Markers of Cardiovascular Disease.
Show details| Abbreviation | Definition |
|---|---|
| I | Broadly applicable study |
| II | Study applicable to sub-group of population |
| III | Narrowly applicable study |
| Δ% | Difference of the marker's profile (post-treatment minus pre-treatment) |
| A | Alpha linolenic acid or “good” quality study (see Summary Table footnotes) |
| AA | Arachidonic acid (20:4 n-6) |
| AC50 | Concentration of collagen giving a 50% decrease in optical density |
| Ad | Adequate allocation concealment |
| ADP | Adenosine diphosphate |
| AHRQ | Agency for Healthcare Research and Quality |
| AI | Adequate Intake |
| ALA | Alpha linolenic acid (18:3 n-3) |
| Allocation Conceal | Allocation concealment |
| apo | Apolipoprotein |
| apo A-I | Apolipoprotein A-I |
| apo B-100 | Apolipoprotein B-100 |
| apo B-48 | Apolipoprotein B-48 |
| apo C-III | Apolipoprotein C-III |
| B | Fair quality study |
| Base | Baseline level in treatment arm |
| BMI | Body mass index |
| C | Poor quality study |
| CAB | Commonwealth Agricultural Bureau |
| CB | Carotid bifurcation |
| CCA | Common carotid artery |
| CI | Confidence interval |
| Cohort Δ | Difference between cohort and reference cohort (cross-sectional) |
| CR | Control rate |
| CRP | C-reactive protein |
| CSFII | Continuing Food Survey of Intakes by Individuals |
| CVD | Cardiovascular disease |
| D | Docosahexaenoic acid |
| DHA | Docosahexaenoic acid (22:6 n-3) |
| DM | Diabetes mellitus |
| DM I | Diabetes mellitus, type 1 |
| DM II | Diabetes mellitus, type 2 |
| DPA | Docosapentaenoic acid (DPA, 22:5 n-3) |
| DysLip | DysLipidemia |
| E | Eicosapentaenoic acid |
| ECG | Electrocardiogram |
| ED | EPA+DHA |
| EE | Ethyl ester |
| ELISA | Enzyme-linked immunosorbent assay |
| EPA | Eicosapentaenoic acid (20:5 n-3) |
| EPC | Evidence-based practice center |
| ERD | Energy-restricted diet |
| ETT | Exercise tolerance test |
| FA | Fatty acid |
| FBS | Fasting blood sugar |
| GEN | General, healthy population |
| GLA | Gamma-linolenic acid (18:3 n-6) |
| HDL | High density lipoprotein |
| Hgb A1c | Hemoglobin A1c |
| Imax | Maximal velocity |
| IC50 | Concentration of Iloprost resulting in 50% inhibition of platelet aggregation |
| ICA | Internal carotid artery |
| IDDM | Insulin dependent diabetes mellitus |
| IDL | Intermediate density lipoprotein |
| IL | Interleukin |
| IMT | Intima-media thickness |
| In | Inadequate allocation concealment |
| Jadad | Jadad score (see Methods) |
| JNC 7 | Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure |
| LA | Linoleic acid (18:2 n-6) |
| LDL | Low density lipoprotein |
| LDL apo B | LDL apolipoprotein B |
| LT | Leukotriene |
| N | Number of subjects analyzed in study arm |
| n-3 | Omega-3 (fatty acid) |
| n-6 | Omega-6 (fatty acid) |
| NCEP | National Cholesterol Education Program |
| NCEP I | National Cholesterol Education Program step I prudent diet |
| nd | No data |
| Net % Δ | Net percent difference in change in omega-3 fatty acids arm compared with the change in control arm |
| Net Δ | Net difference in change in omega-3 fatty acids arm compared with the change in control arm |
| NHANES III | The third National Health and Nutrition Examination |
| NIDDM | Non-insulin dependent diabetes mellitus |
| NIH | National Institutes of Health |
| NS | Non-significant |
| P | P value |
| PAI | Plasminogen activator inhibitor |
| PG | Prostaglandin |
| PL | Phospholipids |
| Pre Post Δ | Change in omega-3 fatty acid arm (no control) |
| PTCA | Percutaneous transluminal coronary angioplasty |
| RBC | Red blood cell |
| RCT | Randomized controlled trial |
| REM MA | Random effects model meta-analysis |
| RPP | Rate-pressure product |
| RR | Relative risk |
| SD | Standard deviation |
| SDNN | Standard deviation of the RR interval |
| SEM | Standard error of the mean |
| SFA | Saturated fatty acid |
| Sp. | Species |
| Summary | Summary quality score (see Methods) |
| T | Total omega-3 fatty acids |
| TEP | Technical Expert Panel |
| Tg | Triglycerides |
| TNF-α | Tumor necrosis factor α |
| TPA | Tissue plasminogen activator |
| TPR | Total peripheral resistance |
| Tufts-NEMC | Tufts-New England Medical Center |
| TX | Thromboxane |
| Un | Unclear allocation concealment |
| UO | University of Ottawa |
| USDA | United States Department of Agriculture |
| Va | Aggregation velocity |
| VCAM-1 | Vascular cell adhesion molecule 1 |
| VLDL | Very low density lipoprotein |
| vWF | von Willebrand factor |
| WBC | White blood cell |
| WMD | Weight-maintaining diet |
| Xover | Cross-over study |
- List of Acronyms/Abbreviations - Effects of Omega-3 Fatty Acids on Cardiovascula...List of Acronyms/Abbreviations - Effects of Omega-3 Fatty Acids on Cardiovascular Risk Factors and Intermediate Markers of Cardiovascular Disease
- Homo sapiens transcription factor Dp-1 (TFDP1), RefSeqGene on chromosome 13Homo sapiens transcription factor Dp-1 (TFDP1), RefSeqGene on chromosome 13gi|345478713|ref|NG_029909.1|Nucleotide
Your browsing activity is empty.
Activity recording is turned off.
See more...